Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.

Cancer research and treatment - 1 Oct 2020

Ogasawara Aiko, Hihara Taro, Shintani Daisuke, Yabuno Akira, Ikeda Yuji, Tai Kenji, Fujiwara Keiichi, Watanabe Keisuke, Hasegawa Kosei

Abstract excerpt

PURPOSE: Circulating tumor DNA (ctDNA) is an attractive source for liquid biopsy to understand molecular phenotypes of a tumor non-invasively, which is also expected to be both a diagnostic and prognostic marker. PIK3CA and KRAS are among the most frequently mutated genes in epithelial ovarian cancer (EOC). In addition, their hotspot mutations have already been identified and are ready for a highly sensitive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ovarian Epithelial
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Liquid Biopsy

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Progression-Free Survival

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 32599986
DOI: 10.4143/crt.2019.688
PMCID: PMC7577815

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations.PMID 32599986Read ↗

Tumor-related mutations in cell-free DNA in pre-operative plasma as a prognostic indicator of recurrence in endometrial cancer.Semantic proximity Read ↗

Detection of circulating tumor DNA in patients of operative colorectal and gastric cancersSemantic proximity Read ↗

Detection of cancer DNA in plasma of patients with early-stage breast cancer.Semantic proximity Read ↗

Comprehensive Gene Mutation Profiling of Circulating Tumor DNA in Ovarian Cancer: Its Pathological and Prognostic ImpactSemantic proximity Read ↗

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers.Semantic proximity Read ↗

Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.Semantic proximity Read ↗

Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer.Semantic proximity Read ↗

Mutations in circulating tumor DNA detected in the postoperative period predict poor survival in patients with ovarian cancer.Semantic proximity Read ↗

Circulating tumor DNA as a prognostic marker in high-risk endometrial cancerSemantic proximity Read ↗

Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer.Semantic proximity Read ↗

Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.Semantic proximity Read ↗

Advances in application of circulating tumor DNA in ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.